JP2018514590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514590A5 JP2018514590A5 JP2018508624A JP2018508624A JP2018514590A5 JP 2018514590 A5 JP2018514590 A5 JP 2018514590A5 JP 2018508624 A JP2018508624 A JP 2018508624A JP 2018508624 A JP2018508624 A JP 2018508624A JP 2018514590 A5 JP2018514590 A5 JP 2018514590A5
- Authority
- JP
- Japan
- Prior art keywords
- retinal
- disease
- composition
- eye
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 13
- 230000002207 retinal effect Effects 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 208000017442 Retinal disease Diseases 0.000 claims 6
- 208000002780 macular degeneration Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 206010038848 Retinal detachment Diseases 0.000 claims 5
- 206010046851 Uveitis Diseases 0.000 claims 5
- 230000006907 apoptotic process Effects 0.000 claims 5
- 230000004264 retinal detachment Effects 0.000 claims 5
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 5
- 230000001154 acute effect Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000030833 cell death Effects 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 239000002736 nonionic surfactant Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 210000000608 photoreceptor cell Anatomy 0.000 claims 3
- 108091008695 photoreceptors Proteins 0.000 claims 3
- 208000004644 retinal vein occlusion Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000014882 Carotid artery disease Diseases 0.000 claims 2
- 208000002691 Choroiditis Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 208000019878 Eales disease Diseases 0.000 claims 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 208000003971 Posterior uveitis Diseases 0.000 claims 2
- 208000002367 Retinal Perforations Diseases 0.000 claims 2
- 206010038910 Retinitis Diseases 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 2
- 108700012411 TNFSF10 Proteins 0.000 claims 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 201000006321 fundus dystrophy Diseases 0.000 claims 2
- 230000003284 homeostatic effect Effects 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 230000021597 necroptosis Effects 0.000 claims 2
- 210000003994 retinal ganglion cell Anatomy 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000006379 syphilis Diseases 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 208000005598 Angioid Streaks Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 claims 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims 1
- 208000033825 Chorioretinal atrophy Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010070957 Choroidal haemangioma Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000021089 Coats disease Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000001351 Epiretinal Membrane Diseases 0.000 claims 1
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000032578 Inherited retinal disease Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 208000031471 Macular fibrosis Diseases 0.000 claims 1
- 208000035719 Maculopathy Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000010164 Multifocal Choroiditis Diseases 0.000 claims 1
- 206010064997 Necrotising retinitis Diseases 0.000 claims 1
- 208000001140 Night Blindness Diseases 0.000 claims 1
- 206010065700 Ocular sarcoidosis Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010065373 Papillophlebitis Diseases 0.000 claims 1
- 208000034247 Pattern dystrophy Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims 1
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000032430 Retinal dystrophy Diseases 0.000 claims 1
- 206010038897 Retinal tear Diseases 0.000 claims 1
- 206010038899 Retinal telangiectasia Diseases 0.000 claims 1
- 206010038915 Retinitis viral Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 208000036038 Subretinal fibrosis Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 206010044269 Toxocariasis Diseases 0.000 claims 1
- 208000027076 Uveal disease Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- 208000029977 White Dot Syndromes Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003093 cationic surfactant Substances 0.000 claims 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 claims 1
- 201000005849 central retinal artery occlusion Diseases 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 208000027129 choroid disease Diseases 0.000 claims 1
- 208000024980 claudication Diseases 0.000 claims 1
- 230000009852 coagulant defect Effects 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims 1
- 230000003619 fibrillary effect Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 208000029233 macular holes Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 201000002165 neuroretinitis Diseases 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 208000008798 osteoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 229940044476 poloxamer 407 Drugs 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 201000004849 posterior scleritis Diseases 0.000 claims 1
- 201000002267 posterior uveal melanoma Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 210000001927 retinal artery Anatomy 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical class CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 claims 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims 1
- 229960004224 tyloxapol Drugs 0.000 claims 1
- 229920001664 tyloxapol Polymers 0.000 claims 1
- 230000003074 vasoproliferative effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021080927A JP2021120400A (ja) | 2015-05-01 | 2021-05-12 | ペプチド組成物および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155711P | 2015-05-01 | 2015-05-01 | |
| US62/155,711 | 2015-05-01 | ||
| PCT/US2016/030098 WO2016178993A1 (en) | 2015-05-01 | 2016-04-29 | Peptide compositions and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021080927A Division JP2021120400A (ja) | 2015-05-01 | 2021-05-12 | ペプチド組成物および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514590A JP2018514590A (ja) | 2018-06-07 |
| JP2018514590A5 true JP2018514590A5 (cg-RX-API-DMAC10.html) | 2019-05-30 |
| JP6884755B2 JP6884755B2 (ja) | 2021-06-09 |
Family
ID=57217771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508624A Active JP6884755B2 (ja) | 2015-05-01 | 2016-04-29 | ペプチド組成物および使用方法 |
| JP2021080927A Pending JP2021120400A (ja) | 2015-05-01 | 2021-05-12 | ペプチド組成物および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021080927A Pending JP2021120400A (ja) | 2015-05-01 | 2021-05-12 | ペプチド組成物および使用方法 |
Country Status (21)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107708416B (zh) | 2015-05-01 | 2021-06-29 | Onl医疗股份有限公司 | 肽组合物和使用方法 |
| WO2019183246A1 (en) * | 2018-03-20 | 2019-09-26 | Onl Therapeutics, Inc. | Compositions and methods of fas inhibition |
| EP3810082A1 (en) * | 2018-06-19 | 2021-04-28 | Cella Therapeutics, LLC | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
| JP2023507603A (ja) * | 2019-12-18 | 2023-02-24 | セラ セラピューティクス エルエルシー | 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系 |
| WO2022266127A1 (en) * | 2021-06-15 | 2022-12-22 | Onl Therapeutics, Inc. | Methods and compositions for treating ocular disorders and diseases |
| WO2023287794A2 (en) * | 2021-07-13 | 2023-01-19 | Onl Therapeutics, Inc. | Methods and compositions for improving visual function in ocular diseases and disorders |
| WO2023129766A1 (en) * | 2021-12-27 | 2023-07-06 | Onl Therapeutics, Inc. | Sfasl for inhibiting rpe cell death and associated disorders |
| EP4565595A2 (en) * | 2022-08-05 | 2025-06-11 | ONL Therapeutics, Inc. | Peptide compositions and methods of use |
| WO2024031024A1 (en) * | 2022-08-05 | 2024-02-08 | Onl Therapeutics, Inc. | Peptide compositions and methods of use |
| WO2024220669A1 (en) * | 2023-04-19 | 2024-10-24 | Onl Therapeutics, Inc. | Methods and compositions for treating rnfl thinning |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5532123A (en) * | 1990-07-11 | 1996-07-02 | New York University | Receptor-type phosphotyrosine phosphatase-γ |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| JP3187201B2 (ja) * | 1992-05-14 | 2001-07-11 | 三共株式会社 | Ｃ末端にプロリンアミドを有するペプチドの製法 |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| JP3460863B2 (ja) | 1993-09-17 | 2003-10-27 | 三菱電機株式会社 | 半導体装置の製造方法 |
| US5714353A (en) | 1994-05-24 | 1998-02-03 | Research Corporation Technologies, Inc. | Safe vectors for gene therapy |
| US5527928A (en) | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
| US5650096A (en) | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5719131A (en) | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
| US5711964A (en) | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6001962A (en) * | 1996-11-15 | 1999-12-14 | The Regents Of The University Of California | Modified Fas ligands |
| US7091047B2 (en) * | 1997-05-23 | 2006-08-15 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity |
| US6363020B1 (en) | 1999-12-06 | 2002-03-26 | Virage Logic Corp. | Architecture with multi-instance redundancy implementation |
| US6480428B2 (en) | 2000-12-19 | 2002-11-12 | Winbond Electronics Corporation | Redundant circuit for memory device |
| JP2008500816A (ja) | 2004-03-31 | 2008-01-17 | ゼンコー・インコーポレイテッド | 改善された性質を有するｂｍｐ−７変異体 |
| EP1737483A2 (en) | 2004-04-23 | 2007-01-03 | University of Pittsburgh of the Commonwealth System of Higher Education | Cell death modulation via antagonists of fasl and fas activation |
| PL1885336T3 (pl) | 2005-05-10 | 2009-08-31 | Alcon Inc | Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu |
| KR20080065704A (ko) * | 2005-11-09 | 2008-07-14 | 콤비네이토릭스, 인코포레이티드 | 의학적 이상의 치료 방법들, 조성물들, 및 키트들 |
| CA2631731A1 (en) * | 2005-12-01 | 2007-06-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compounds and methods for inhibiting apoptosis |
| AU2008345689B2 (en) * | 2007-12-21 | 2013-04-18 | Stryker Corporation | BMP mutants with decreased susceptibility to Noggin |
| US8343931B2 (en) * | 2009-03-03 | 2013-01-01 | The Regents Of The University Of Michigan | Methods of inhibiting photoreceptor apoptosis |
| CA2756864A1 (en) * | 2009-03-30 | 2010-10-07 | Santen Pharmaceutical Co., Ltd. | Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase)-inhibitory peptide, and use of the peptide |
| EP2462128B1 (en) * | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| BR112013021494B1 (pt) | 2011-02-22 | 2021-09-08 | California Institute Of Technology | Vetor viral, polinucleotídeo isolado, uso de um vírus adeno-associado (aav) recombinante e método para produzir o mesmo |
| JP6250536B2 (ja) * | 2011-06-06 | 2017-12-20 | ケイ・ブイ・１．３・セラピューティクス・インコーポレイテッド | Ｓｈｋベースの薬学的組成物とその製造方法および使用方法 |
| US9428550B2 (en) | 2012-01-18 | 2016-08-30 | Governing Council Of The University Of Toronto | Peptides and methods and uses thereof for preventing retinal disorders |
| BR112014031923B1 (pt) * | 2012-06-21 | 2022-02-08 | Daewoong Pharmaceutical Co., Ltd. | Uso de uma composição compreendendo pelo menos um tnfri modificado ou fragmento tnfri modificado, uso de uma formulação tópica e uso de uma composição |
| CA2890238A1 (en) * | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| WO2016125148A1 (en) | 2015-02-05 | 2016-08-11 | Immunarray Ltd. | Methods and compositions for diagnosing brain injury or neurodegeneration |
| CN107708416B (zh) * | 2015-05-01 | 2021-06-29 | Onl医疗股份有限公司 | 肽组合物和使用方法 |
| US20190201500A1 (en) | 2015-05-01 | 2019-07-04 | Onl Therapeutics, Inc. | Compositions and methods of fas inhibition |
| CN110177577A (zh) | 2016-07-05 | 2019-08-27 | 马萨诸塞大学 | Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法 |
| AU2018290228B2 (en) | 2017-06-21 | 2021-07-01 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV gp120 and CD3 |
| WO2019183246A1 (en) | 2018-03-20 | 2019-09-26 | Onl Therapeutics, Inc. | Compositions and methods of fas inhibition |
| EP3810082A1 (en) | 2018-06-19 | 2021-04-28 | Cella Therapeutics, LLC | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
-
2016
- 2016-04-29 CN CN201680038258.8A patent/CN107708416B/zh active Active
- 2016-04-29 EP EP25186051.6A patent/EP4623925A2/en active Pending
- 2016-04-29 EP EP16789830.3A patent/EP3288379B1/en active Active
- 2016-04-29 CA CA2984154A patent/CA2984154A1/en active Pending
- 2016-04-29 PT PT167898303T patent/PT3288379T/pt unknown
- 2016-04-29 EP EP21200594.6A patent/EP3997981A1/en not_active Withdrawn
- 2016-04-29 LT LTEPPCT/US2016/030098T patent/LT3288379T/lt unknown
- 2016-04-29 US US15/570,948 patent/US10508134B2/en active Active
- 2016-04-29 RS RS20220095A patent/RS62866B1/sr unknown
- 2016-04-29 AU AU2016258837A patent/AU2016258837B2/en active Active
- 2016-04-29 HU HUE16789830A patent/HUE057883T2/hu unknown
- 2016-04-29 WO PCT/US2016/030098 patent/WO2016178993A1/en not_active Ceased
- 2016-04-29 KR KR1020247010090A patent/KR20240046280A/ko not_active Ceased
- 2016-04-29 KR KR1020177034366A patent/KR102652804B1/ko active Active
- 2016-04-29 EA EA202090184A patent/EA202090184A3/ru unknown
- 2016-04-29 ES ES16789830T patent/ES2906173T3/es active Active
- 2016-04-29 SI SI201631458T patent/SI3288379T1/sl unknown
- 2016-04-29 MX MX2017014075A patent/MX387317B/es unknown
- 2016-04-29 HR HRP20220138TT patent/HRP20220138T1/hr unknown
- 2016-04-29 SM SM20220069T patent/SMT202200069T1/it unknown
- 2016-04-29 EA EA201792399A patent/EA035293B1/ru unknown
- 2016-04-29 JP JP2018508624A patent/JP6884755B2/ja active Active
- 2016-04-29 CN CN202110665678.1A patent/CN113651873B/zh active Active
- 2016-04-29 DK DK16789830.3T patent/DK3288379T3/da active
- 2016-04-29 PL PL16789830T patent/PL3288379T3/pl unknown
-
2019
- 2019-11-04 US US16/673,513 patent/US10829518B2/en active Active
-
2020
- 2020-10-06 US US17/064,495 patent/US11597749B2/en active Active
-
2021
- 2021-05-12 JP JP2021080927A patent/JP2021120400A/ja active Pending
-
2022
- 2022-02-02 CY CY20221100088T patent/CY1124911T1/el unknown
-
2023
- 2023-01-24 US US18/159,021 patent/US12258425B2/en active Active
-
2025
- 2025-02-14 US US19/054,490 patent/US20250346631A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514590A5 (cg-RX-API-DMAC10.html) | ||
| HRP20220138T1 (hr) | Peptidni pripravci i postupci uporabe | |
| JP2020530470A5 (cg-RX-API-DMAC10.html) | ||
| KR20160126983A (ko) | 안내 혈관신생 및/또는 누출 치료용 조성물 및 방법 | |
| JP2007535552A5 (cg-RX-API-DMAC10.html) | ||
| JP2015520130A5 (cg-RX-API-DMAC10.html) | ||
| JP2019510078A5 (cg-RX-API-DMAC10.html) | ||
| JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
| US20170172959A1 (en) | D-serine for the treatment of visual system disorders | |
| AU2004296748B2 (en) | Prevention and/or reduction of photoreceptor degeneration with retinoids | |
| KR20120081585A (ko) | 안질환을 치료하기 위한 이소티오졸 | |
| US20110257186A1 (en) | Compositions and methods for treating visual disorders | |
| JP2014521648A (ja) | 網膜疾患を治療するための４−ブロモ−ｎ−（イミダゾリジン−２−イリデン）−１ｈ−ベンゾイミダゾール−５−アミンを含む医薬組成物 | |
| JP2013523892A5 (cg-RX-API-DMAC10.html) | ||
| RU2019114205A (ru) | Способы лечения глазного заболевания с применением ингибиторов csf-1r | |
| WO2012066994A1 (ja) | 神経保護作用を持つ薬剤配合 | |
| MXPA06006024A (es) | Prevencion y/o reduccion, con retinoides de la degeneracion de fotorreceptores |